Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on April 1, 2016, to report the completion of its reincorporation from the State of Florida to the State of Delaware. The Company's principal executive offices remain in Carmiel, Israel.
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Reincorporation: The Company is now subject to the General Corporation Laws of the State of Delaware.
- Continuity: There were no substantial changes to the rights, privileges, or powers of the Company. All assets, debts, liabilities, and obligations remain unchanged.
- Leadership: There was no change in officers or directors.
- Securities: All outstanding shares of common stock and options/rights to acquire shares prior to reincorporation remain outstanding and valid.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the legal mechanics of the reincorporation and the attachment of the new Certificate of Incorporation and Bylaws.
Investor Verification Checklist
- Verify the attached exhibits (Certificate of Incorporation and Bylaws) to confirm the specific terms of the Delaware charter.
- Confirm that existing stock options and rights have been automatically carried over without modification.
- Review subsequent filings for any operational or financial updates, as this 8-K contains no financial data.